Media

Select from the drop-down menu below to read the most up-to-date news about pelareorep.

May 31, 2024 | Poster
Phase 1/2 Randomized, Open-label, Multicenter, Simon Two-stage Study of Pelareorep Combined with Modified FOLFIRINOX +/- Atezolizumab in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Arnold, Dirk et al, Previously presented at the 2024 American Society of Clinical Oncology Annual Meeting; 2024 May 31 – June 4
December 6, 2023 | Poster
T Cell Receptor Sequencing to Monitor Pelareorep-Induced Expansion of Tumor Infiltrating Lymphocytes 
Trauger, Richard et al, Previously presented at the 2023 San Antonio Breast Cancer Symposium®; December 5-9, 2023
November 9, 2023 | Poster
GOBLET: A phase 1/2 multiple indication study in advanced gastrointestinal cancers treated with pelareorep and atezolizumab – preliminary safety and efficacy results in second-line or later unresectable anal carcinoma
Arnold, Dirk et al. Previously presented at The 2nd International Multidisciplinary Anal Cancer Conference (IMACC) 2023, Nov. 9-10, 2023
November 3, 2023 | Poster
Analysis of the HR+/HER2- breast cancer tumor microenvironment following immune priming with pelareorep and atezolizumab using imaging mass cytometry – Results from the AWARE-1 trial
Olea, Julian et al. Previously presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, November 1-5, 2023
October 23, 2023 | Poster
Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients – Results from the GOBLET study
Arnold, Dirk et al. Previously presented at ESMO Congress 2023, Oct. 23, 2023
October 23, 2023 | Poster
Pelareorep + atezolizumab and chemotherapy in third-line (3L) metastatic colorectal cancer (mCRC) patients – Interim results from the GOBLET study
Ungerechts, Guy et al. Previously presented at ESMO Congress 2023, Oct. 22, 2023
October 3, 2023 | Poster
Multiplex analysis of the tumor immune microenvironment during treatment with atezolizumab/pelareorep/letrozole reveals novel immune-tumor interactions
Dadrastoussi, Homa et al.
June 2, 2023 | Poster
BRACELET-1 (PrE0113): Inducing an Inflammatory Phenotype in Metastatic HR+/HER2- Breast Cancer with the Oncolytic Reovirus Pelareorep in Combination with Paclitaxel and Avelumab
Clark, Amy et al. Previously presented at the 2023 ASCO Annual Meeting; 2023 Jun 2-6.
June 2, 2023 | Poster
Efficacy of Function-enhanced, Re-activatable, Dual-specific CAR T cells Pre-loaded with Oncolytic Virus for Immunotherapy of High-Grade Glioma
Webb, Mason et al. Previously presented at the 2023 ASCO Annual Meeting; 2023 Jun 2-6.
December 1, 2022 | Poster
A multicenter, single-arm, open-label Phase I study of AN1004 (Pelareorep) oncolytic virus plus paclitaxel inChinese patients with Hormone receptor-positive and HER2-negative advanced/metastatic breast cancer (REO 026-1)
Li, Wei et al, Previously presented at the 2022 San Antonio Breast Cancer Symposium®; December 6-10, 2022
December 1, 2022 | Poster
Pelareorep primes the tumor for checkpoint inhibition therapy by activating the interferon-gamma signaling pathway andtumor inflammation signature in early breast cancer patients – results of the AWARE-1 trial
H. Loghmani, J Gavila, L. Manso, R. Trauger, F. Salvador, T. Pascual, A. Prat, Matt Coffey, T. Heineman
November 10, 2022 | Suggested Media
Oncolytics Presents Promising Pancreatic Cancer Data at SITC
November 8, 2022 | Poster
Pelareorep combined with atezolizumab and chemotherapy demonstrates encouraging results as first-line treatment in advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients – Interim results from the GOBLET study
Arnold, Dirk et al, Previously presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting; November 8-12, 2022
November 8, 2022 | Poster
The oncolytic virus pelareorep in combination with immune checkpoint inhibitor activates T-cell functioning in early breast cancer patients – immunophenotype results from AWARE-1 study
González-Navarro, E.A et al, Previously presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting; November 8-12, 2022
June 29, 2022 | Poster
GOBLET: A phase 1/2 multiple indication signal finding and biomarker study in advanced gastrointestinal cancers treated with pelareorepand atezolizumab –safety and preliminary response results
Collienne, Maike et al, Previously presented at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022; June 29 – July 2, 2022

Contact Us

For questions regarding our science, partnership opportunities, or other inquiries, we encourage you to reach out.

Get in touch